Management of CIN 2 in patients whose concerns about the effects of treatment on a future pregnancy outweigh their concerns about cancer
This algorithm describes management of CIN 2 in patients whose concerns about the effects of treatment on a future pregnancy outweigh their concerns about cancer. Also addressed is the management of histologic HSIL not further specified in women younger than 25 years, for whom observation is acceptable, and for women 25 years or older for whom treatment is preferred.
From: Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102. DOI:
10.1097/LGT.0000000000000525. Copyright © 2020 the American Society for Colposcopy and Cervical Pathology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
